3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Completed
5
Recruiting
4
Terminated
2
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
2
Conditions
Breast Neoplasms
6
Triple Negative Breast Neoplasms
4
Ovarian Neoplasms
3
Neoplasms
2
Fallopian Tube Neoplasms
2
Triple Negative Metastatic Breast Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Pancreatic Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Gemcitabine
34
pembrolizumab
26
Paclitaxel
21
Cyclophosphamide
21
Docetaxel
20
Carboplatin
20
Irinotecan
19
Capecitabine
19
Fluorouracil
17
Bevacizumab
15
Dexamethasone
14
fludarabine
13
Oxaliplatin
13
Leucovorin
13
Blood Specimen Collection
13
Everolimus
12
Cetuximab
12
Ipilimumab
11
Erlotinib Hydrochloride
11
Rituximab
10
Pemetrexed
10
Cisplatin
10
venetoclax
9
Temozolomide
9
Sunitinib
9
Nivolumab
9
Trastuzumab
8
Interleukin-2
8
aldesleukin
7
Epoetin Alfa
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Neoplasms
×
talazoparib
×
Clear all
NCT05097599
2025-01-08
StrataPATH
Strata Oncology
Phase 2
Terminated
11 enrolled
NCT04801966
2023-05-10
TAILOR
Peter MacCallum Cancer Centre, Australia
Phase NA
Terminated
3 enrolled